Tirzepatide

Tirzepatide is a peptide studied as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Research examines whether engaging both incretin pathways produces effects that differ from GLP-1 agonism alone. It has been evaluated in large randomized clinical trials in type 2 diabetes and obesity, and in smaller trials exploring liver disease and cardiovascular outcomes.

Tirzepatide is studied at both the GIP and GLP-1 receptors, and its GIP activity distinguishes it from single-receptor GLP-1 agonists. Research has explored its combined effects on insulin signaling, gastric emptying, and satiety. Mechanistic work published in JCI Insight described it as an imbalanced and biased dual agonist, meaning its activity at the two receptors and their downstream signaling pathways is not equivalent.

Phase 3 trials have examined glycemic control in type 2 diabetes, including SURPASS-1 and a head-to-head comparison with semaglutide. The SURMOUNT-4 trial studied continued use for maintenance of weight reduction in adults with obesity, and a later trial compared it with semaglutide for obesity. Other studies have examined appetite, energy intake, and fat mass, liver fibrosis in steatohepatitis, and cardiovascular events versus dulaglutide.

Safety was assessed alongside efficacy in phase 3 trials such as SURPASS-1, and cardiovascular safety is being evaluated against dulaglutide in the SURPASS-CVOT trial. Specific adverse event types and rates are not summarized in this overview. Because the compound acts on gastric emptying as part of its studied mechanism, gastrointestinal effects are an area of research attention. Researchers should consult the primary trial publications for detailed safety findings.

Research protocols have used 1.5 to 15 mg per administration, given subcutaneously once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. The reported cycle was continuous until target weight loss. These figures describe what published protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.